A real-world study comparing efficacy and safety of CPX-351 versus 7+3 in patients with secondary acute myeloid leukemia
Latest Information Update: 12 Jan 2021
At a glance
- Drugs Cytarabine (Primary) ; Cytarabine/daunorubicin (Primary) ; Daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 12 Jan 2021 New trial record
- 08 Dec 2020 Primary endpoint (response rate) has not been met.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology